Home > Resources > Whitepapers > Dialogue / Advancing Meaningful Patient Engagement in Research, Development, and Review of Drugs

Dialogue / Advancing Meaningful Patient Engagement in Research, Development, and Review of Drugs

September 22, 2015

On March 2, 2015, the National Health Council (NHC) and Genetic Alliance hosted an invitation-only Dialogue Event at the offi ces of the Food and Drug Administration (FDA) in Silver Spring, Maryland, including thought leaders involved in patient engagement policy, research, and implementation. Thirty-two participants representing the FDA, patient organizations, academia, and industry gathered to discuss key issues surrounding patient engagement in product research, development, and approval. By providing a forum for these thought leaders to share their perspectives, experiences, and expertise, the hosts hoped to establish a common vision to help drive meaningful integration of the patient voice in the product development and approval processes.

Spotlight

Editas Medicine

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

OTHER WHITEPAPERS

Your Ultimate Guide to CMC Testing Support for Gene and Cell Therapy

whitePaper | December 6, 2022

The development of Advanced Therapy Medicinal Products such as gene and cell therapy products, has made significant progress in the treatment of many diseases, including cancer, genetic, and autoimmune disorders.

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Becoming a life sciences superpower

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Growing a circular economy with fungal biotechnology

whitePaper | August 17, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans.

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins